SC-236
SC-236 is a selective cyclooxygenase-2 (COX-2) inhibitor that has been studied for its potential use in treating inflammation and pain. COX-2 inhibitors are a class of drugs that specifically target the COX-2 enzyme, which is responsible for the synthesis of pro-inflammatory prostaglandins.
Mechanism of Action[edit | edit source]
SC-236 works by selectively inhibiting the COX-2 enzyme, thereby reducing the production of pro-inflammatory prostaglandins. This action helps to alleviate inflammation and pain without affecting the COX-1 enzyme, which is important for maintaining the protective lining of the stomach and regulating blood platelets.
Pharmacokinetics[edit | edit source]
The pharmacokinetics of SC-236 involve its absorption, distribution, metabolism, and excretion. SC-236 is absorbed into the bloodstream after oral administration and is distributed throughout the body. It is metabolized primarily in the liver and excreted through the kidneys.
Clinical Applications[edit | edit source]
SC-236 has been investigated for its potential use in treating conditions such as arthritis, cancer, and other inflammatory diseases. Its selective inhibition of COX-2 makes it a promising candidate for reducing inflammation with fewer gastrointestinal side effects compared to non-selective NSAIDs.
Research and Development[edit | edit source]
Research on SC-236 has focused on its efficacy and safety profile. Studies have shown that SC-236 can effectively reduce inflammation and pain in animal models. However, further clinical trials are necessary to fully understand its potential benefits and risks in humans.
Side Effects[edit | edit source]
As with other COX-2 inhibitors, potential side effects of SC-236 may include cardiovascular risks, such as an increased risk of heart attack or stroke. Gastrointestinal side effects are generally less common compared to non-selective NSAIDs.
Regulatory Status[edit | edit source]
As of the latest updates, SC-236 is still under investigation and has not been approved for clinical use by major regulatory agencies such as the FDA or EMA.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
